This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada’s achievements in meeting a range of...

This paper examines aspects of the policy environment and market characteristics of the Swiss pharmaceutical sector, and assesses the degree to which Switzerland has achieved certain policy goals. In Switzerland, pharmaceutical spending has not been growing faster than health expenditure as a...

This paper describes pharmaceutical pricing and reimbursement policies in Germany, considering them in the broader environment in which they operate, and assesses their impact on the achievement of a number of policy goals. Pharmaceutical coverage is comprehensive, with a high level of public...

This paper examines aspects of the policy environment and market characteristics of the Swiss pharmaceutical sector, and assesses the degree to which Switzerland has achieved certain policy goals. In Switzerland, pharmaceutical spending has not been growing faster than health expenditure as a...

This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada’s achievements in meeting a range of...

[fre] Âge, temps et normes : une analyse de la prescription pharmaceutique par Pierre- Jean Lancry et Valérie Paris . La mise en place de politiques cohérentes de régulation des dépenses de santé nécessite la définition de variables de commande susceptibles de modifier les comportements...

[eng] Pharmaceutical industry regulation . Pharmaceutical industry regulation pursues three goals : respond to public health concerns, limit collective drug expenditures, and ensure competitiveness of national industry. The first goal issues are dealing with the assessment of the benefits/risks...

This study analyses how 14 OECD Countries refer to “value” when making decisions on reimbursement and prices of new medicines. It details the type of outcomes considered, the perspective and methods adopted for economic evaluation when used; and the consideration of budget impact. It describes...

[ger] Die Eindâmmung der Arzneimitteikosten in Deutschiand, Frankreich und im Vereinigten Kônigreich . Deutschiand, Frankreich und das Vereinigte Kônigreich haben im Laufe der letzten zehn Jahre verschiedene MaBnahmen erprobt, die auf eine Eindâmmung des . Anstiegs der von der Allgemeinheit...

In 2008, the OECD launched a survey to collect information on the health systems characteristics of member countries. This paper presents the informaton provided by 29 of these countries in 2009. It describes country-specific arrangements to organise the population coverage against health risks...